News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Oxford BioMedica PLC (OXB.L) to Present at Conference


8/29/2012 9:49:54 AM

OXFORD, UNITED KINGDOM--(Marketwire - August 29, 2012) -


Oxford BioMedica to Present at the 2012 Rodman & Renshaw Annual Global
Investment Conference



-- 14th Annual Healthcare Conference --



Oxford, UK - 29 August 2012: Oxford BioMedica plc ("Oxford BioMedica"
or "the Company") (LSE: OXB), the leading gene-based biopharmaceutical
company, today announces that John Dawson, Chief Executive Officer of
Oxford BioMedica, will present at the Rodman & Renshaw Annual Global
Investment Conference to be held on September 9-11, 2012 at The Waldorf
Astoria, NY (USA).



The presentation is scheduled for Monday, 10 September 2012 at 16:30
Eastern Time. A copy of the slide presentation will be made available
on the "Investors/Corporate presentations" section of the Company's
website at www.oxfordbiomedica.co.uk.



-Ends-



For further information, please contact:

Oxford BioMedica plc:                              Tel: +44 (0)1865 783
                                                   000
Lara Mott, Head of Corporate Communications

Media Enquiries:                                   Tel: +44 (0)20 7920
                                                   2360
Mary Clark/Sarah Macleod/Claire Dickinson
M:Communications




Notes to editors



1. Oxford BioMedica®

Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company
developing innovative gene-based medicines and therapeutic vaccines
that aim to improve the lives of patients with high unmet medical
needs. The Company's technology platform includes a highly efficient
LentiVector® gene delivery system, which has specific advantages for
targeting diseases of the central nervous system and the eye; and a
unique tumour antigen (5T4), which is an ideal target for anti-cancer
therapy. Through in-house and collaborative research, Oxford BioMedica
has a broad pipeline with current partners and licensees including
Sanofi, Pfizer, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec,
Emergent BioSolutions and ImaginAb. Further information is available
at www.oxfordbiomedica.co.uk.

                    This information is provided by RNS
          The company news service from the London Stock Exchange

END

Contacts:
RNS
Customer
Services
0044-207797-4400
Email Contact
http://www.rns.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES